Compare ARVN & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | ORN |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 555.4M |
| IPO Year | 2018 | 2007 |
| Metric | ARVN | ORN |
|---|---|---|
| Price | $8.96 | $14.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $15.05 | ★ $16.25 |
| AVG Volume (30 Days) | ★ 854.3K | 390.1K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.84 | ★ 220.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | $262,600,000.00 | ★ $852,260,000.00 |
| Revenue This Year | N/A | $8.50 |
| Revenue Next Year | N/A | $7.83 |
| P/E Ratio | ★ N/A | $117.08 |
| Revenue Growth | N/A | ★ 7.01 |
| 52 Week Low | $6.06 | $6.44 |
| 52 Week High | $14.22 | $15.85 |
| Indicator | ARVN | ORN |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 55.31 |
| Support Level | $7.35 | $10.01 |
| Resistance Level | $10.18 | $15.00 |
| Average True Range (ATR) | 0.51 | 0.70 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 23.34 | 40.74 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.